Temperature Regulation. This article establishes an indispensable role for the prostaglandin (PG) E 2 -synthesizing enzyme, microsomal PGE synthase (mPGES)-1, in two models of experimental fever: interleukin (IL)-1␤ induced and turpentine induced. These findings should be viewed in the context of the major breakthroughs and setbacks that have marked the development of antipyretic and anti-inflammatory pharmacotherapy in the recent past.
Several promising targets have been recently suggested (for review, see Ref. 9) , and mPGES-1, the subject of the study of Saha et al. (18) , is one such target.
Identified by Jakobsson et al. (13) , mPGES-1 is a 16-kDa member of the so-called MAPEG (membrane-associated proteins involved in eicosanoid and glutathione metabolism) family, which catalyzes the final step of the PGE 2 synthesis: a nonoxidative rearrangement of the COX product PGH 2 into PGE 2 . Not only does this enzyme occupy the terminal position in the PGE 2 -synthesizing cascade, but it also preferentially couples with "bad" COX, COX-2 (3, 16) . Not surprisingly, mPGES-1 is uniquely positioned to catalyze inflammationassociated PGE 2 synthesis. In rats, high (120 -400 g/kg) doses of bacterial lipopolysaccharide (LPS) were shown to increase mPGES-1 mRNA and protein levels in the brain and in many peripheral organs, including the lungs and spleen (14, 16, 24) . In the brain, the message was localized in the vasculature, and the protein was abundant in the perinuclear envelope of endothelial cells, where mPGES-1 was colocalized with COX-2 (24). The febrile response of rats to a low dose of LPS (50 g/kg) was also accompanied by strong transcriptional upregulation of the mPGES-1 gene in peripheral LPSprocessing organs (the liver and lungs) and in the brain (10) . In the latter study, remarkable features of the mPGES-1 response were its high magnitude and long duration. Indeed, the expression of this gene was upregulated more than 1,200 fold in the liver and more than 30-fold in the lungs and hypothalamus. This upregulation persisted for several hours after a single injection of LPS. Even when COX-2 expression had returned to its baseline, mPGES-1 remained overexpressed (10) . An endogenous pyrogen, IL-1␤, was also found to induce mPGES-1 in brain vascular cells, presumably endotheliocytes and perivascular macrophages (4). Undisputable evidence for the crucial involvement of mPGES-1 in LPS fever was obtained by Engblom et al. (5) and Saha et al. (18) by using the recently developed mice with deletion of the Ptges gene, which encodes mPGES-1 (21, 22) . These mice showed no fever and no central PGE 2 synthesis after peripheral injection of LPS, but they displayed an intact pyretic capacity in response to centrally administered PGE 2 (5). These mice also showed drastically reduced or completely abolished fevers in response to peripheral IL-1␤ or turpentine but had a normal circadian rhythm of body temperature and developed the same hyperthermia in response to a psychogenic stressor as their wild-type littermates (18) .
The most downstream position of mPGES-1 in the PGE 2 -synthesizing cascade makes this enzyme potentially the most selective target for antipyretic and anti-inflammatory therapy. The highest magnitude of upregulation of mPGES-1 among all PGE 2 -synthesizing enzymes studied during LPS fever, the long duration of this upregulation, and the fact that mPGES-1 is strongly upregulated when expression of COX-2 declines (10) further increase the attractiveness of this target. That mPGES-1 is indispensable for the development of the febrile response to LPS (5) and other pyrogens [as demonstrated by Saha et al. in this issue (18) ] warrants even more optimism. Will the next big news from the producers of Vioxx, Celebrex, Bextra, and other "coxibs" be positive? Will it be about mPGES-1?
